Sachi Okawa Hiroe Kayatani Keiichi Fujiwara Taichi Ozeki Kenji Takada Yoshitaka Iwamoto Daisuke Minami Ken Sato Takuo Shibayama
10.2169/internalmedicine.1001-18
Intern Med
2019;58(5):699-702.
autoimmune hemolytic anemia hemophagocytic lymphohistiocytosis immune checkpoint inhibitors non-small cell lung cancer pembrolizumab
CC BY-NC-ND
https://pubmed.ncbi.nlm.nih.gov/30828042/
Anemia, Hemolytic, Autoimmune / drug therapy Antibodies, Monoclonal, Humanized / adverse effects Antibodies, Monoclonal, Humanized / therapeutic use Carcinoma, Non-Small-Cell Lung / drug therapy Carcinoma, Squamous Cell / drug therapy Lung Neoplasms / drug therapy Lymphohistiocytosis, Hemophagocytic / drug therapy
Anemia, Hemolytic, Autoimmune / drug therapy Antibodies, Monoclonal, Humanized / adverse effects Antibodies, Monoclonal, Humanized / therapeutic use Carcinoma, Non-Small-Cell Lung / drug therapy Carcinoma, Squamous Cell / drug therapy Lung Neoplasms / drug therapy Lymphohistiocytosis, Hemophagocytic / drug therapy Case Reports Aged Anemia, Hemolytic, Autoimmune / etiology Coombs Test Glucocorticoids / therapeutic use Humans Jaundice / drug therapy Jaundice / etiology Lymphohistiocytosis, Hemophagocytic / etiology Male Prednisolone / therapeutic use Treatment Outcome Antibodies, Monoclonal, Humanized Glucocorticoids Prednisolone pembrolizumab
PMC6443545
30828042
Pembrolizumab-induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in Non-small Cell Lung Cancer
2019